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Structured Abstract:  
Context: Weight loss and improved blood glucose control after bariatric surgery have been attributed in part to 
increased ileal nutrient delivery with enhanced release of glucagon-like peptide 1 (GLP-1). Non-surgical strategies to 
manage obesity are required. The aim of the current study was to assess whether encapsulated glutamine, targetted 
to the ileum, could increase GLP-1 secretion, improve glucose tolerance or reduce meal size. 
Methods: A single-centre, randomised, double blind, placebo-controlled, cross-over study was performed in 24 
healthy volunteers and 8 patients with type 2 diabetes. Fasting participants received a single dose of encapsulated 
ileal-release glutamine (3.6 or 6.0g) or placebo per visit with blood sampling at baseline and for 4 hours thereafter. 
Glucose tolerance and meal size were studied using a 75g oral glucose tolerance test and ad libitum meal 
respectively.  
Results: In healthy volunteers, ingestion of 6.0 g glutamine was associated with increased GLP-1 concentrations after 
90 min compared with placebo (mean 10.6 pg/ml vs 6.9 pg/ml, p=0.004), increased insulin concentrations after 90 
min (mean 70.9 vs 48.5, p=0.048), and increased meal size at 120 min (mean 542g eaten vs 481g, p=0.008). Ingestion 
of 6.0g glutamine was not associated with significant differences in GLP-1, glucose or insulin concentrations after a 
glucose tolerance test in healthy or type 2 diabetic participants.  
Conclusions: Single oral dosing of encapsulated glutamine did not provoke consistent increases in GLP-1 and insulin 
secretion and was not associated with beneficial metabolic effects in healthy volunteers or patients with type 2 
diabetes.  
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Introduction  
 
Over several decades, population levels of obesity, defined as individuals having a body mass index of 30 kg/m2 or 
more, have increased in many countries worldwide. The World Health Organisation now considers obesity to be one 
of the greatest public health challenges to be faced in the 21st century(1). Obesity and related conditions, such as 
type 2 diabetes mellitus (T2DM), are responsible for rising healthcare costs and a great burden of morbidity and 
mortality. Both obesity and T2DM can be successfully treated with bariatric surgery, although the precise 
mechanisms responsible for these beneficial effects remain poorly understood. One possibility is that bariatric 
surgery improves diabetes and aids weight loss by increasing nutrient delivery to the distal gut, which stimulates 
release of the satiety-promoting incretin hormone glucagon-like peptide 1 (GLP-1).  Although GLP-1 mimetics have 
been given pharmacologically in the treatment of T2DM and obesity(2), an alternative would be to use agents which 
enhance endogenous GLP-1 production to harness similar benefits with potentially fewer adverse effects.  
GLP-1 is produced in enteroendocrine L-cells in the mucosa of the ileum and colon in response to nutrient exposure. 
Many different proteins or amino acids have been found to stimulate GLP-1 release by interacting with the calcium-
sensing receptor (CaSR)(3, 4), GPRC6A(5) or PEPT1(4). The amino acid glutamine is abundant in the human diet and a 
particularly effective stimulant of GLP-1 release in vitro because it not only generates an electrical signal in L-cells 
but also elevates intracellular cAMP levels(6). Oral ingestion of glutamine in human volunteers was associated with 
enhanced GLP-1 secretion and improved glucose tolerance, but a dose of at least 15g was required(7, 8), possibly 
due to the low stability of glutamine in gastric acid(9) and its absorption in the upper GI tract resulting in relatively 
low levels reaching the ileal L-cells. Encapsulation could circumvent this problem by facilitating targeted release of 
nutrients into parts of the intestine where the L-cells are most abundant. 
The aim of the current study was to assess the effect of encapsulated glutamine on GLP-1 concentrations, glucose 
tolerance and meal size in healthy human volunteers and in individuals with T2DM.  
 
Methods  
Participant Recruitment 
Healthy male and female volunteers (18-65 years old; body mass index (BMI) 18-35 kg/m2) were recruited using 
advertisements in Addenbrooke’s Hospital and the University of Cambridge. Patients with T2DM (18-65 years old; 
BMI of 18-40 kg/m2) were identified through primary care, outpatient clinics and using advertisements. Participants 
with anaemia or other significant active diseases and those who were pregnant or breastfeeding were excluded. 
Patients with T2DM who had taken insulin or injectable GLP-1 agonists were excluded from the study. Patients who 
were taking metformin, sulphonylureas or dipeptidyl peptidase-IV (DPP-IV) inhibitors were asked to withhold these 
for 12, 24 and 72 hours prior to the test respectively.  
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Participants were provided with written information about the study and gave written informed consent prior to 
participation. The study was given ethical approval by the Norfolk & Norwich research ethics committee (Reference 
12/EE/0389, 25/09/2012; ISRCTN 10757078).  
 
Participants attended the clinical research facility in the morning following an overnight fast. The evening before 
each visit, participants had a standardised pasta meal (15% protein, 30% fat, 55% carbohydrate) designed to provide 
33% of their daily calorie requirement based upon an estimation of their metabolic rate and activity levels(10).  
 
Capsule Production 
Capsule development and GMP manufacture was performed by Encap Drug Delivery Ltd (Livingston, UK). Each 
capsule contained 600mg of glutamine or 300mg microcrystalline cellulose (placebo). The capsules were 
manufactured with an enteric coating designed to promote capsule release 20 minutes after exposure to an alkaline 
environment.  
Study Design 
The capsules were tested in a series of blinded, controlled studies in human volunteers. The primary endpoint was 
the effect of the capsules upon circulating concentrations of total GLP-1 in venous blood. The secondary endpoints 
were safety, the effect of the capsules upon glucose tolerance, meal size and subjective feelings of hunger and 
fullness.  
Fasting study: Initially, a single-blinded, non-randomised, placebo-controlled dose-ranging study in four healthy 
volunteers was performed to ascertain the optimal dose for further evaluation and provide preliminary safety data. 
The doses studied included placebo (10 capsules) and 0.6g, 1.8g. 3.6g and 6.0g glutamine supplemented where 
necessary with placebo capsules to preserve participant blinding. The remainder of the study used the two most 
promising doses, 3.6 and 6.0g Glutamine in comparison to placebo in a double-blind, controlled randomised design.  
 On each visit, venous blood was taken at baseline and at intervals following capsule ingestion for evaluation of GLP-
1 concentrations. Participants recorded adverse events in a symptom diary and completed questionnaires evaluating 
hunger, fullness and nausea. On one visit, participants had a DXA scan. Ten healthy volunteers were recruited for 
evaluation of the primary endpoint in the fasting comparison between placebo, 3.6g Glutamine and 6.0g Glutamine.  
Glucose tolerance and meal size in healthy volunteers and patients with T2DM: For evaluation of the effect on the 
capsules on glucose tolerance, nine healthy volunteers and eight patients with T2DM were recruited. The study visits 
were similar to the fasting study except that each participant had a 75g oral glucose tolerance test (OGTT) at 90 
minutes after capsule ingestion.  
Meal size in healthy volunteers: For evaluation of the effect of the capsules on meal size, ten healthy volunteers 
were recruited to attend the Clinical Research Facility on three occasions for an ad libitum breakfast given 120 
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minutes after capsule ingestion. The ad libitum meal consisted of muesli with chopped fruit, nuts and milk in a 
homogenous mixture designed to provide 15% protein, 30% fat and 55% carbohydrate. A portion of 1.5 kg (2400 
kcals) was provided on each occasion and participants were advised to eat until they felt full. The total amount of 
food eaten was measured using a universal eating monitor.  
Questionnaire Design 
Hunger, fullness and nausea were assessed using a visual analogue scale which has been widely used in the medical 
literature(11).  
Analytical Methodology 
For analysis of total GLP-1, samples were taken into EDTA plasma tubes, placed on ice immediately after venesection 
and centrifuged (3500g at 4oC 10 minutes), aliquotted and frozen using dry ice within 15 minutes of venesection. 
Samples were stored at -80oC prior to batch analysis in duplicate of GLP-1 using the Mesoscale Discovery Total GLP-1 
kit, a sandwich immunoassay with electrochemiluminescence detection which measures all endogenous forms of 
GLP-1. This method has a range of 1.4-1000 pg/ml and coefficients of variation (CVs) of 5-7%.  
For biochemistry testing, serum samples were allowed to clot for 10 minutes then centrifuged, separated and frozen 
within 30 minutes of venesection and stored at -80oC prior to analysis. Glucose, alanine aminotransferase (ALT) and 
creatinine were measured in a clinically-accredited laboratory at Addenbrooke’s hospital using a Siemens’ Dimension 
analyser with CVs of <2% within the reference range. Thyroid stimulating hormone (TSH) was measured using a 
Bayer ADVIA Centaur immunoassay system with CVs of <6% within the reference range. HbA1c was measured on 
fresh whole blood using a Tosoh analyser with CVs of <5% within the reference range.   
For measurement of insulin, samples were collected into lithium heparin plasma tubes, placed on ice, centrifuged 
(3500g at 4oC 10 minutes), aliquotted and frozen using dry ice within 15 minutes of venesection. Samples were 
stored at -80oC prior to batch analysis using the Diasorin Liaison, an immunoassay with chemiluminescent detection. 
This method has a range of 20-3470 pmol/l and intra-assay CVs of <5%.  
Statistical Analysis 
Based on previous work (7), using a paired study design, it was estimated that observing 8 subjects per comparison 
would have 90% power to detect an average difference of 6.0 pmol/l (19.8 pg/ml) of GLP-1. For each endpoint, 8-10 
participants were recruited to allow for participant withdrawal. Plasma concentrations of hormones and analytes in 
the text and figures are shown as mean ± SEM. 
As this was a cross-over study, each participant was given placebo and active regimens in randomised order, using a 
pre-prepared protocol developed using a random number generation package. Paired t tests were used to compare 
plasma levels of GLP-1, glucose and insulin and reported levels of hunger, fullness and nausea according to a visual 
analogue scale. Peak GLP-1 was defined as the maximum concentration of GLP-1 for an individual on a simgle study 
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day.  Peak GLP-1 was defined as the maximum concentration of GLP-1 for an individual on a single study day.  Linear 
regression was used to assess the differences between GLP-1, glucose and insulin concentrations between groups. 
STATA/SE 13.1 was used for analysis.  
 
Results  
32 participants were recruited (24 healthy volunteers and 8 patients with T2DM). The baseline characteristics of the 
participants are listed in table 1. Most healthy volunteers were aged 22-30 years old with a body mass index of 20-25 
kg/m2 and around 25% body fat.  As expected, the patients with T2DM were generally older and had a higher BMI, 
percentage fat mass and HbA1c compared to healthy volunteers. Most participants had normal haemoglobin, white 
cell count, ALT, TSH and creatinine at baseline.  
Table 1: Baseline characteristics of study participants – characteristics shown as median (range). HV: healthy volunteers; T2DM: patients 
with type 2 diabetes mellitus. Data represent mean + SD. 
 HV: Assessment 
of GLP-1 
concentrations 
n=10 
HV: Assessment of 
glucose tolerance  
n=9 
HV: Assessment of 
meal size§  
n=10 
T2DM: Assessment 
of glucose tolerance 
n=8 
Gender 5 male, 5 female  4 male, 5 female  5 male, 5 female 4 male, 4 female 
Age (years at enrolment) 31.3 (9.7) 36.2 (10.5) 33.9 (10.2) 57.9 (10.7) 
Body Mass Index kg/m
2
 22.9 (3.5) 25.0 (3.9) 23.4 (4.1) 32.5 (5.6) 
Waist circumference cm 79.0 (14.0) 88.3 (11.5)  83.1 (15.5) 104.0 (16.8)  
Hip circumference cm 94 (10)  102 (8) 96 (11) 120 (10) 
DXA Percentage fat mass 23.8 (11.3) 29.3 (12.5)  29.1 (12.4) 41.8 (8.0) 
Haemoglobin g/l 136 (13)  138 (14) 135 (15) 136 (16)  
White Cell Count *10
9
/l 5.1 (0.7) 5.3 (1.1) 4.8 (1.0) 6.7 (1.0) 
Platelets *10
9
/l 189 (25) 225 (52) 197 (30) 165 (82) 
Creatinine umol/l 70.5 (11.8)  67.3 (11.0) 64.0 (8.9) 70.9 (10.4)  
ALT IU/l 32.5 (23.8) 36.4 (25.9)  33.6 (27.6) 46.0 (23.3) 
TSH U/l 2.0 (0.8) 2.1 (0.6) 2.0 (0.9) 1.9 (1.0) 
HbA1c mmol/mol 36.0 (4.2) 36.9 (3.4) 36.4 (3.6) 57.6 (17.6) 
§ Only 8 of these participants had blood taken and a DXA scan. 
Dose ranging study:  Assessment of the dose-related effects of glutamine capsules on circulating concentrations of 
total GLP-1 in fasting healthy volunteers 
Four healthy volunteers were recruited to identify the optimal dose for further study.  The highest dose, 6.0g 
Glutamine, was associated with a significant increase in peak GLP-1 concentration compared to placebo during  
(figure 1). Based on these results, the doses chosen for further study were 3.6g Glutamine and 6.0g Glutamine in 
comparison to placebo.  
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Figure 1: Results of the dose ranging study. 4 blinded healthy volunteers attended on 3-4 occasions for administration of increasing doses of 
glutamine. The doses chosen for further study were 3.6g and 6.0g in comparison to placebo. Capsules were administered at time 0, 
immediately after baseline blood samples were taken. Data represent mean + SEM.  
 
 
 
Assessment of the effect of glutamine capsules on circulating concentrations of total GLP-1 in healthy volunteers 
Ten healthy volunteers were recruited to assess the effect of glutamine capsules on GLP-1 concentrations (table 1; 
fig.2). Ingestion of 6.0g glutamine was associated with an increase in peak GLP-1 (mean + SEM: 7.5 + 4.1 pg/ml 
placebo vs 10.3 + 2.6 pg/ml with 6.0g glutamine; p<0.001).  The area under the curve (AUC) for GLP-1 (from 0-240 
minutes) was not significantly different (1217 + 154 vs 1484 + 241 pg*min/ml for placebo and 6.0g Glutamine 
respectively). There was no significant difference in peak or AUC glucose, insulin, hunger, fullness or nausea between 
the regimens.  
These results were different from those found during the dose-ranging study (fig. 1). Further examination of 
individual participants’ data showed one group (n=7) with increased GLP-1 concentrations (responders) while other 
participants (n=3) showed no evidence of a GLP-1 response. In responders, the shape of the GLP-1 curve was 
heterogeneous with marked differences between participants. There was also marked intra-individual variation in 
fasting GLP-1 concentrations in some participants between each of the three visits which was not explained by 
altered diet or exercise patterns within 24 hours of the study visit.  
Assessment of the effect of glutamine capsules on glucose tolerance in healthy volunteers 
Nine healthy volunteers were recruited to assess the effect of glutamine capsules on glucose tolerance using an oral 
glucose tolerance test (OGTT; table 1; fig. 3). After ingestion of 6.0g Glutamine, participants had significantly higher 
concentrations of insulin (mean + SEM: 70.9 + 13.4 vs 48.5 + 7.8  pmol/l; p=0.048) and GLP-1 (10.6 + 1.0 vs 6.9 + 0.8 
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pg/ml; p=0.004) at 90 minutes, i.e. immediately prior to ingestion of the 75g glucose load. No significant difference 
was seen in the area under the curve before or after the OGTT for glucose, GLP-1, insulin, hunger, fullness or nausea.  
The effect of encapsulated nutrients on concentrations of GLP-1, glucose and insulin in patients with type 2 diabetes.  
Eight patients with T2DM were enrolled into the study and attended for two visits for the assessment of hormone 
concentrations and glucose tolerance using an OGTT given at 90 minutes (table 1; fig. 4) after placebo or 6.0g 
glutamine. There were no significant differences in peak concentrations of glucose, GLP-1 or insulin or in reported 
levels of hunger, fullness or nausea. Area under the curve before or after the OGTT for glucose, GLP-1 and insulin 
were similar between active and placebo treatment regimens.  
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Figure 2: Effect of encapsulated glutamine upon concentrations of total GLP-1, insulin and glucose, and subjective measurements of hunger, 
fullness and nausea in fasting subjects. Capsules were administered at time 0, immediately after baseline blood samples were taken. 10 
participants attended on 3 occasions and took either placebo, 3,6g Glutamine or 6.0g Glutamine in a randomised, blinded, cross-over 
design. Data represent mean + SEM.  
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Figure 3: Effect of encapsulated glutamine upon concentrations of total GLP-1, insulin and glucose, and subjective measurements of hunger, 
fullness and nausea in healthy subjects before and after an oral glucose tolerance test (OGTT) which was given immediately after the 90 
minute sampling. Capsules were administered at time 0, immediately after baseline blood samples were taken. 10 participants attended on 
3 occasions and took placebo, 3,6g Glutamine or 6.0g Glutamine in a randomised, blinded, cross-over design. Data represent mean + SEM.  
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Figure 4: : Effect of encapsulated glutamine upon concentrations of total GLP-1, insulin and glucose, and subjective measurements of 
hunger, fullness and nausea in subjects with type 2 diabetes before and after an oral glucose tolerance test (OGTT) which was given 
immediately after the 90 minute sampling. Capsules were administered at time 0, immediately after baseline blood samples were taken. 8 
participants attended on 2 occasions and took either placebo or 6.0g Glutamine in a randomised, blinded, cross-over design. Data represent 
mean + SEM.  
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Figure 5: The effect of encapsulated glutamine on meal size, hunger, fullness and nausea in healthy volunteers. Capsules were administered 
at time 0, immediately after baseline blood samples were taken. An ad libitum meal was consumed 120 minutes later. a:  Volunteers ate 
significantly more following ingestion of the 6.0g Glutamine capsules compared to placebo. b-d: Assessment of hunger, fullness and nausea 
during and after the ad libitum meal. Data are presented as mean + SEM. The symbol ** denotes significance at p<0.01 respectively using 
paired t test analysis comparing the 6.0g Glutamine dose with placebo.  
 
Assessment of the effect of glutamine capsules on meal size 
Ten healthy volunteers were recruited to assess the effect of glutamine capsules on meal size (table 1). The group 
receiving 6.0g Glutamine  ate significantly more food during the ad libitum meal compared to the placebo group 
(mean 542 + 65g eaten vs 481 + 71g, p=0.008; fig. 5) and had reduced hunger scores postprandially (reduced area 
under the curve from 120-480 minutes, p=0.053; and 0-480 minutes, p=0.031). 
This finding was unexpected and contrary to the hypothesis. Unfortunately, no blood samples were taken from 
participants during the meal visit. However, participants had significantly higher hunger scores at 120min following 
ingestion of 6g glutamine, before beginning the meal. On linear regression analysis, hunger at 120 minutes was 
linearly related to the amount eaten when the model was adjusted for gender (coefficient 3.41, 95% confidence 
interval 0.12-6.7, p=0.042).  
Assessment of the effect of glutamine capsules on hunger and satiety 
Overall, there was no significant difference between peak or AUC for hunger, fullness or nausea for these variables 
between the three different regimens (figs 2-4) except during the meal study (fig 5). Hunger and fullness were 
linearly related and hunger scores tended to be lower where nausea scores were high (fig S1).  
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Discussion  
This study demonstrates that up to 6g of encapsulated glutamine is unable to provoke a physiologically or clinically 
significant increase in plasma total GLP-1 concentrations in fasting healthy volunteers and is not associated with 
beneficial effects upon glucose tolerance or meal size. As evident by comparing the results shown in figures 1 and 2, 
some individuals showed small responses to capsule ingestion. However, the magnitude of these responses is likely 
to be inadequate to cause clinically beneficial effects.  
 
This study used a double-blind, randomised, placebo-controlled, cross-over design to reduce bias and the effects of 
inter-individual variation. The encapsulated glutamine was tested in healthy individuals and in patients with type 2 
diabetes. The capsules were designed to release their contents around 20 minutes after exposure to an alkaline 
medium, corresponding broadly to the upper-to-mid ileum. Gastrointestinal transit has not been measured and is 
likely to vary between individuals, but the capsules were all taken in the fasting state in order to minimise variation 
in transit time through the stomach. It is possible that not all capsules left the stomach at the same time, which 
might result in a different profile of glutamine exposure along the gastrointestinal tract and may in part explain 
inter-individual differences in response. Due to inter and intra-individual variations in gastrointestinal motility, 
gastric and intestinal secretion volumes and capsule opening profiles, it is not possible to know what concentration 
of glutamine was reached in the intestinal lumen. These factors might explain why the small GLP-1 responses to 
capsule ingestion observed in some subjects were not apparent in others. Theoretically, the dissolution of ten 
capsules simultaneously could trigger a sharp but short-lived GLP-1 response while more gradual dissolution of the 
capsules may give a more gradual GLP-1 release profile. It is likely, however, that the dose of glutamine was the 
limiting factor in this experiment. As ten capsules were required to give a dose of 6g glutamine, further dose 
increases were not considered feasible within this study design.  
 
The study was powered according to published data and had 90% power to detect an average difference in GLP-1 of 
6.0 pmol/l (20 pg/ml). However, as the difference in peak GLP-1 seen in the fasting state during this study was much 
lower than this, our study was not powered to detect such small effect sizes. It also remains unclear what levels of 
GLP-1 might be required to provoke a meaningful change in clinical endpoints such as glucose tolerance and weight 
reduction. In this study, in the fasting state, GLP-1 concentrations peaked at ~10 pg/ml, well below the 
concentrations expected following even a small meal(12).   Indeed, GLP-1 concentrations rose much higher to 20-35 
pg/ml after the OGTT. Bariatric surgery has been associated with postprandial total GLP-1 concentrations of 100-160 
pmol/l (330-520 pg/ml)(13).  
 
Glutamine is known to be associated with increased GLP-1 secretion and beneficial metabolic effects both in healthy 
volunteers and in patients with type 2 diabetes. Glutamine is known to elevate cAMP and cytosolic calcium in ileal L-
cells and is likely to bind to the calcium sensing receptor (CASR) (14)and the sodium-dependent transporters such as 
SLC38A2 and SLC6A19(6) L-cells also express a range of alternative G-protein coupled receptors, which might be 
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targetable by dietary nutrients or high affinity ligands(15) As the EC50 for glutamine-triggered GLP-1 secretion in 
vitro was 0.2 mM(6), we speculate that the dose of glutamine delivered in the capsules was too low to activate L-
cells along a large length of the small intestine.    Previous work by Greenfield and colleagues has shown that 30g of 
oral glutamine in 300ml water can stimulate increases in GLP-1 and insulin in healthy and obese volunteers and 
patients with type 2 diabetes(7) with mean peak GLP-1 concentrations of around 22 pmol/l (72 pg/ml) in lean 
healthy volunteers. This has led to the hypotheses that glutamine could be developed therapeutically in patients 
with impaired glucose tolerance or diabetes (7). However, the mode of delivery in that study was challenging as 30g 
of glutamine is incompletely soluble in 300ml water and a ‘swish and swallow’ approach was required (7, 16). 
Furthermore, 30g glutamine has a calorie content of around 120 kcals and providing additional calories to patients 
with obesity or type 2 diabetes may exacerbate glucose tolerance through weight gain. The aim of the current 
approach was to identify if increases in gut hormone concentrations and beneficial metabolic effects could be 
harnessed using low doses of glutamine using an alternative delivery method which aimed to maximise the exposure 
of glutamine to lower intestinal L-cells. This approach was not, however, associated with an increase in circulating 
GLP-1 concentrations comparable to the magnitude of effects seen in Greenfield’s study. Glucose concentrations 
were also not affected by glutamine ingestion in this study, a finding which is consistent with Greenfield’s work (7). 
Chang and colleagues tested an alternative method of delivery involving intra-duodenal infusion of 7.5-15g 
glutamine (17). They found relatively small increases in GLP-1 (in healthy volunteers and patients with T2DM) and 
insulin (T2DM only) although their participants demonstrated higher baseline total GLP-1 concentrations than those 
seen in this study, possibly due to the different analytical methods used for GLP-1 analysis. Their finding of low GLP-1 
responses to the 7.5g glutamine infusion is consistent with our results, and together both reports suggest that the 
dose of glutamine is limiting, even when administered directly into the small intestine. 
 
One unexpected finding in our study was the increase in meal size which occurred following ingestion of glutamine in 
comparison to placebo. As GLP-1 is generally considered to be anorexigenic, and 6.0g glutamine has a caloric value 
of around 30 kcal, an association between glutamine and reduced meal size might have been expected rather than 
the converse. Although blood tests were not taken during the meal test, participants who received the 6.0g 
glutamine dose prior to an OGTT had slightly higher circulating concentrations of GLP-1 and insulin prior to the start 
of the OGTT compared to individuals who received placebo (fig. 3). As insulin is considered to be orexigenic(18), it is 
possible that the increased insulin may explain the increased meal size consumed by participants. It is possible, 
however, that other gut hormones or targets of glutamine might play a role.  
 
No significant difference between concentrations of GLP-1, insulin or glucose after consumption of the glutamine 
capsules in comparison to placebo were found in subjects with type 2 diabetes. In patients with diabetes, responses 
may be complicated by altered background GLP-1 secretory patterns(19, 20), gastric emptying(21), or intestinal 
responsiveness to amino acids in patients taking metformin(22).  
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In conclusion, orally-administered glutamine capsules did not provoke a consistent increase in GLP-1 or insulin in 
human volunteers and was not associated with beneficial effects upon glucose tolerance or meal size. We speculate 
that the low dose of glutamine that could be administered in capsular form was limiting in this study, and suggest 
that the success of future capsule-based approaches to trigger GLP-1 release will be dependent, at least in part, on 
the choice of higher affinity ligands to receptors localised on L-cells. Further work is needed to identify if other 
nutritional products could function as more potent agonists to promote endogenous GLP-1 secretion and harness its 
clinical benefits.  
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Supplementary information:  Safety Report 
The assessment of safety was a secondary endpoint of the study and was assessed using a symptom diary and visual 
analogue scale for nausea. There were no serious adverse events during the study although a wide variety of 
symptoms were reported (table S1).  
 
Table S1: Symptoms experienced according to treatment regimen given (individual participant identification number given in brackets). 
Symptoms after Placebo Symptoms after 6g Glutamine  Symptoms after 3.6g Glutamine  
Dizzy, headache (P2) 
Breathlessness & sensation of 
tachycardia (P2) 
Nausea (P13) 
Shakiness ?hypoglycaemia (P20) 
Nausea and vomiting (P21) 
Light-headedness (P23) 
Headache (P12) 
Headache (P13) 
Uncomfortably full & abdominal pain (P14) 
Flatulence (P15) 
Abdominal discomfort & vomiting (P16) 
Felt less hungry for several hours (P20) 
Dizzy (P9) 
Headache, backache(P12) 
Constipation (P12) 
 
 
 
 
 
Results from the symptom diaries showed that side-effects were experienced following administration of all 
regimens (Table S1). The vast majority of symptoms were classified as mild (1-3/10 on a visual analogue scale).  
Symptoms tended to fall within 3 broad categories: 
 Symptoms related to the protocol, commonly associated with fasting. These included mild headache, 
dizziness and light-headedness and were broadly similar across all treatment groups.  
 Gastrointestinal symptoms occurred including nausea, vomiting, constipation, flatulence and abdominal 
discomfort. Most symptoms within this category were mild. Two participants experienced vomiting episodes 
after placebo and 6g glutamine doses. Two participants specifically mentioned nausea on their symptom 
diary following ingestion of placebo capsules. One of these participants reported nausea after ingestion of 
the OGTT and the visit had to be abandoned after emesis of the intact capsules. 
 Other events:  
o One participant experienced tremor after the test and attributed her symptoms to hypoglycaemia, 
although no testing facilities were available as she had left the hospital. The symptoms resolved 
quickly after eating and occurred after a placebo visit.  
o One participant experienced breathlessness and the sensation of tachycardia after her first visit. On 
assessment of her observations including saturations, clinical examination and electrocardiogram, 
no concerning abnormalities were identified. These symptoms occurred during a placebo visit and 
resolved quickly after reassurance.  
 
When using the visual analogue scores, participants put a cross on a 100mm line to indicate how hungry, full or 
nauseated they felt at each timepoint. As expected, there was a small negative association between nausea and 
hunger, and a strong negative correlation between hunger and fullness (fig. S1). There was a small significant 
association between GLP-1 concentrations and nausea (fig. S1). Most participants experienced no nausea during the 
study.  
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Figure S1: Relationships between visual analogue scores and/or GLP-1 concentrations in all participants at all timepoints excluding the meal 
visits when blood was not was taken. A: Most participants experienced no nausea during the test. There was a small but significant positive 
relationship between GLP-1 concentration and nausea scores. B: There was a small negative correlation between nausea and hunger. C: 
There was a strong negative correlation between hunger and fullness. Statistical analysis was performed using linear regression.  
 
In conclusion, side effects occurred in both glutamine and placebo groups. Fasting was associated with dizziness, 
headache and light-headedness. Gastrointestinal symptoms were common in active and placebo groups with no 
particular evidence of clustering in the 6.0g glutamine group.  However, there was a small but significant relationship 
between nausea and total GLP-1 concentrations.  
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